Trial Profile
A randomized phase II study of pegylated arginine deiminase in advanced hepatocellular carcinoma in Taiwan.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2009
Price :
$35
*
At a glance
- Drugs Pegargiminase (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Polaris Pharmaceuticals
- 22 Jan 2009 New trial record.